.

Deeper Knowledge, Faster

  • Find suppliers and generic API sources
  • Identify first generic entrants
  • Drug patents in 130+ countries

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Covington
Cantor Fitzgerald
Deloitte
Julphar
Farmers Insurance
Boehringer Ingelheim
Cerilliant
Colorcon
McKinsey
Chubb

Generated: June 25, 2017

DrugPatentWatch Database Preview

FARYDAK Drug Profile

« Back to Dashboard

What is the patent landscape for Farydak, and when can generic versions of Farydak launch?

Farydak is a drug marketed by Novartis Pharms Corp and is included in one NDA. There are five patents protecting this drug.

This drug has one hundred and one patent family members in forty-four countries.

The generic ingredient in FARYDAK is panobinostat lactate. One supplier is listed for this compound. Additional details are available on the panobinostat lactate profile page.

Summary for Tradename: FARYDAK

Patents:5
Applicants:1
NDAs:1
Suppliers / Packagers: see list1
Bulk Api Vendors: see list71
Clinical Trials: see list5
Patent Applications: see list1
Drug Prices:see details
DailyMed Link:FARYDAK at DailyMed

Pharmacology for Tradename: FARYDAK

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Novartis Pharms Corp
FARYDAK
panobinostat lactate
CAPSULE;ORAL205353-001Feb 23, 2015RXYesNo6,552,065► SubscribeYY ► Subscribe
Novartis Pharms Corp
FARYDAK
panobinostat lactate
CAPSULE;ORAL205353-003Feb 23, 2015RXYesYes7,067,551► Subscribe ► Subscribe
Novartis Pharms Corp
FARYDAK
panobinostat lactate
CAPSULE;ORAL205353-001Feb 23, 2015RXYesNo► Subscribe► Subscribe
Novartis Pharms Corp
FARYDAK
panobinostat lactate
CAPSULE;ORAL205353-001Feb 23, 2015RXYesNo7,067,551► Subscribe ► Subscribe
Novartis Pharms Corp
FARYDAK
panobinostat lactate
CAPSULE;ORAL205353-002Feb 23, 2015RXYesNo7,067,551► Subscribe ► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Tradename: FARYDAK

Country Document Number Estimated Expiration
China101232880► Subscribe
Philippines12012501725► Subscribe
Argentina035057► Subscribe
Hungary229796► Subscribe
Honduras2008001862► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Supplementary Protection Certificates for Tradename: FARYDAK

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
90070-7Sweden► SubscribePRODUCT NAME: PANOBINOSTAT OR A PHARMACEUTICALLY ACCEPTABLE SALTTHEREOF; REG. NO/DATE: EU/1/15/1023 20150901
2016003Lithuania► SubscribePRODUCT NAME: PANOBINOSTATAS; REGISTRATION NO/DATE: EU/1/15/1023 20120828
0160001 00181Estonia► SubscribePRODUCT NAME: PANOBINOSTAAT;REG NO/DATE: EU/1/15/1023 01.09.2015
2015000098Germany► SubscribePRODUCT NAME: PANOBINOSTAT ODER EIN PHARMAZEUTISCH ANNEHMBARES SALZ ODER DERIVAT HIERVON; REGISTRATION NO/DATE: EU/1/15/1023 20150828
890Luxembourg► SubscribePRODUCT NAME: PANOBINSTAT OU UN SEL PHARMACEUTIQUEMENT ACCEPTABLE , OU UN DERIVE DE CELUI-CI (FARYDAK); FIRST REGISTRATION: 20150901
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Dow
UBS
Baxter
Novartis
Farmers Insurance
Express Scripts
US Department of Justice
Citi
Cantor Fitzgerald
Cerilliant

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot